Becker's Healthcare January 2, 2025
Alexandra Murphy

Pharmacy benefit managers are coming under growing scrutiny as policymakers push for reforms to address their role in rising drug prices, The Wall Street Journal reported Dec. 30.

Here are four things to know:

  1. A recent bipartisan budget bill aimed at reforming PBM practices, including transparency and decoupling their compensation from drug rebates was scrapped after opposition from President-elect Donald Trump allies. While the reforms are no longer a part of the legislation, the issue remains on the table.
  2. Despite the bill’s failure, both Democrats and Republicans including President-elect Trump are increasingly critical of...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Congress / White House, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Ono pays $280M to license Ionis rare disease drug

Share This Article